MTOR and neoplasm: Using a CD34+ humanized PDX model representative of a metastatic pS6high uLMS, we demonstrate that pharmacological inhibition of the PI3K/mTOR pathway elicits anti‐tumour immune responses and sensitises these tumours to PD‐1 blockade.